Latest Results

October 24, 2018

FY2018 3Q Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
426,440 (195,013) (50,442) (70,882) (12,191)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
97,912 23.0 95,632 70,872 128.60

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
890,843 269,872 620,971 (22,843) (128,352)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
738,977 27.9 83.0 62.00  (Forecast) 31.00

Revenues: 426.4 billion JPY (+38.8, +10.0% YoY)

  • Domestic sales excl. Tamiflu®: despite impact from HIP revision, slight increase due to continued growth of sales of mainstay products (+0.9, +0.3%)
  • Overseas sales: growth of Actemra® and Alecensa® export to Roche (+24.1, +32.7%)
  • Royalties and other operating income: one-time income from transfer of long-listed products on HIP list, etc. (+14.8, +64.6%)

Cost of sales / Operating expenses (Core basis)

  • Cost of sales: the ratio to sales improved due to a change in product sales mix, etc. (-0.9% points, from 50.9% to 50.0%)
  • Operating expenses: overall increase mainly due to increase of research and development expenses (-5.5, +4.5%)

Profits

  • IFRS results:  
    operating profit  97.9 billion JPY (+21.7, +28.5%)
    net income  70.9 billion JPY (+13.0, +22.5%)
  • Core results:  
    operating profit  103.3 billion JPY (+24.6, +31.3%)
    net income  74.6 billion JPY (+14.9, +25.0%)
    EPS  135.14 JPY (+27.34, +25.4%)

Jan-Sep 2018 Sales excluding Tamiflu®

Core Operating Income Jan-Sep

  • *Amounts are rounded to the nearest 0.1 billion yen.
    Variance and % are calculated based on amounts shown.

More Information

Quarterly Reports

  • Like
  • Tweet
  • LINE it!
  • E-mail

Financial Results

Back to top